AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The company strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, in addition to products and services across its Allergan Aesthetics portfolio.

For more information about AbbVie, please visit us visit Follow us on Twitter, YouTube.


Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realise new science’s promise by bringing safe, effective medicines from the lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to help improve people’s lives.

For more information about Amgen, our pioneering science and our vital medicines, visit


Pioneering in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases in addition to related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a portfolio of medicines and potential therapies in neuromuscular, neurodegenerative, acute neurology, and ophthalmology disease areas. Biogen believes that biosimilars, and their associated cost-savings, are fundamental to safeguarding future healthcare, and is focusing on advancing one of the most diversified pipelines in neuroscience, transforming the standards of care for patients in several areas of high unmet need.

In 2020, Biogen launched a 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.

​​​​​​​To learn more, please visit,

Bristol Myers Squibb

Bristol Myers Squibb Pharmaceuticals Ltd (BMS) is a global BioPharma company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of patients in their fight against cancer, cardiovascular disease, diabetes, hepatitis B, HIV, rheumatoid arthritis and psychiatric disorders. BMS has a significant presence in the UK, with sites in Uxbridge and the North West of England, and a comprehensive clinical trials programme, in all stages of development, taking place across the country.

See for more information.


Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, hepatitis, serious respiratory and cardiovascular conditions, cancer and inflammation. Gilead was founded in 1987 in Foster City, California and has become a leading biopharmaceutical company with a rapidly expanding product portfolio and over 14,000 employees over 35 countries.

Please visit for more information.


Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases, vaccines, and cardiovascular and metabolic diseases. Driven by its commitment to patients, Janssen brings innovative products, services and solutions to people throughout the world. The legal entity for Janssen in the UK and Ireland is Janssen-Cilag Ltd.

Please visit for more information.


Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world’s most urgent medical needs.

Lilly has a long heritage in the UK, opening its first facility outside North America in London in 1934. Today Lilly has around 700 talented employees in the UK working across two sites in roles such as regulatory affairs, medical affairs, marketing, and communications.

Additional information about Lilly is available at


MSD believe the most important thing it makes is a difference. Through its prescription medicines, vaccines, biologic therapies, consumer care and animal health products, MSD works with customers and operates in more than 140 countries to bring innovative healthcare solutions to those who need them the most. MSD also demonstrate its commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information, visit

MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.


Pfizer is the world’s largest research-based biopharmaceutical company, operating in 180 countries and employing more than 100,000 people worldwide. Pfizer has a diversified global health care portfolio which includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Pfizer is an industry leader in vaccines and biologics, and has a leading presence in inflammation and haemophilia. In the UK, Pfizer is a major supplier of medicines to the NHS with headquarters in Tadworth, Surrey. Pfizer has a strong research heritage in the country with R&D facilities in Cambridge undertaking studies at the forefront of current understanding in pain and regenerative medicine.

Please visit to find out more.



Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign.

Please visit to find out more.